| Code | CSB-RA624104MB8HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Roconkibart, designed for research targeting interleukin-17A (IL-17A), a pro-inflammatory cytokine critical in immune system regulation. IL-17A is primarily produced by Th17 cells and plays a central role in host defense against extracellular pathogens by inducing inflammatory responses and recruiting neutrophils to sites of infection. Dysregulated IL-17A signaling has been implicated in numerous autoimmune and inflammatory conditions, including psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, and inflammatory bowel disease, making it an important therapeutic target.
Roconkibart is a humanized IgG1 monoclonal antibody that specifically binds and neutralizes IL-17A, preventing its interaction with the IL-17 receptor. This biosimilar antibody provides researchers with a valuable tool for investigating IL-17A-mediated pathways, studying inflammatory disease mechanisms, evaluating cytokine neutralization strategies, and exploring immune response modulation in various experimental models. It serves as an essential reagent for advancing understanding of Th17 cell biology and IL-17A-driven pathological processes.
There are currently no reviews for this product.